NEW YORK (GenomeWeb News) - Investment firm Caris & Company upgraded Illumina's stock to "Buy" from "Above Average" today.
The broker cited "removal of Markman ruling overhang" as the reason behind the upgrade.
Separately today, investment bank UBS lifted Affymetrix' price target to $20 from $18.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.